Healthcare: Will Shire Be Bought Out? Plus, Alkermes Suffers a Setback
Industry Focus - A podcast by The Motley Fool
Categorie:
Takeda may buy Shire, but it might prove costly. Also, the FDA slaps Alkermes with a dreaded Refusal to File letter.
Industry Focus - A podcast by The Motley Fool
Takeda may buy Shire, but it might prove costly. Also, the FDA slaps Alkermes with a dreaded Refusal to File letter.